德国拜耳利伐沙班好用吗

It is a highly selective, oral drug that directly inhibits factor Xa. It is produced by Bayer in Germany and is approved for use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis. Rivaroxaban selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert activity. Factor X is activated into factor Xa (FXa) through endogenous and exogenous pathways, which plays an important role in the coagulation cascade.

Bayer is a life sciences company with a history of more than 150 years and is headquartered in Leverkusen, Germany. Bayer continues to improve the quality of life for a growing number of people with an increasing life expectancy by focusing on disease prevention, mitigation and treatment in its research and development activities. So is Bayer's rivaroxaban useful?

Eisenberg MJ et al. meta-analyzed five randomized controlled studies (a total of 23,063 patients were included in rivaroxaban for ≥1 month, including 14,264 cases of non-valvular atrial fibrillation, 3967 cases of deep vein thrombosis, and 3967 cases of acute symptomatic pulmonary embolism). The results found that compared with vitamin K antagonists, rivaroxaban did not increase the composite endpoint of major bleeding and clinically relevant bleeding (RR: 0.99, confidence interval: 0.93 - 1.06), and fatal bleeding events were significantly reduced in the rivaroxaban group (RR: 0.48, CI: 0.31 – 0.74).

For patients with acute coronary syndrome, the ATLAS ACS 2–TIMI 51 trial (enrolled 15,526 patients divided into 2 groups: 2.5 mg twice daily and 5 mg twice daily, The dosage of aspirin in each group (75-100mg/day) showed that rivaroxaban in the two groups significantly reduced primary endpoints including cardiovascular death, myocardial infarction and stroke, while rivaroxaban in the low-dose group reduced secondary endpoints including cardiovascular death and all-cause death.

Recommended related hot articles: /newsDetail/90030.html